Supplementary Data:

Supplementary Figures:

doi: 10.5281/zenodo.3959839

**Supplementary Figure 1.** Cancer-specific Survival of Uveal Melanoma Patients by Diagnosis Era (A, C, D, E) and Tumor Stage (B, F,G,H)

Supplementary tables:

doi: 10.5281/zenodo.3959846
Standardized incidence Ratios for developing a second malignancy after First Primary Uveal Melanoma -
- for age groups:
  - younger than 50 years old, **Supplementary table 1**
  - patients 50-70 years old, **Supplementary table 2**
  - patients older than 70 years old, **Supplementary table 3**
- in white patients, **Supplementary table 4**.

doi: 10.5281/zenodo.3959843
Standardized incidence ratios for developing a primary uveal melanoma following another primary malignancy -
- for age groups:
  - younger than 50 years old, **Supplementary table 5**
  - patients 50-70 years old, **Supplementary table 6**
  - patients older than 70 years old, **Supplementary table 7**
- in white patients, **Supplementary Table 8**

The following tables have no DOI
**Supplementary Table 9, a complementary to table 4**
**Supplementary Table 10, a complementary to table 5**
Supplementary table 1. Standardized incidence Ratios for developing a second malignancy after First Primary Uveal Melanoma in patients younger than 50 years old; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>15</td>
<td>1.36 (0.76-2.24)</td>
<td>20</td>
<td>1.41 (0.86-2.17)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>8</td>
<td>1.49 (0.64-2.93)</td>
<td>10</td>
<td>1.29 (0.62-2.38)</td>
</tr>
<tr>
<td>Female</td>
<td>7</td>
<td>1.24 (0.50-2.56)</td>
<td>10</td>
<td>1.55 (0.74-2.84)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>15</td>
<td>1.41 (0.79-2.33)</td>
<td>20</td>
<td>1.46 (0.89-2.26)</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>0 (0.04-9.46)</td>
<td>0</td>
<td>0 (0.03-6.82)</td>
</tr>
<tr>
<td>Other races</td>
<td>0</td>
<td>0 (0.04-9.46)</td>
<td>0</td>
<td>0 (0.03-6.82)</td>
</tr>
<tr>
<td>Primary site of uveal melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>13</td>
<td>1.46 (0.78-2.50)</td>
<td>13</td>
<td>1.15 (0.61-1.96)</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>2</td>
<td>0.93 (0.11-3.36)</td>
<td>7</td>
<td>2.43 (0.98-5.01)</td>
</tr>
<tr>
<td>Histology of uveal melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8720/3: Malignant melanoma, NOS</td>
<td>9</td>
<td>1.34 (0.61-2.55)</td>
<td>8</td>
<td>0.98 (0.42-1.92)</td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>0</td>
<td>0 (0.04-9.10)</td>
<td>0</td>
<td>0 (0.03-6.27)</td>
</tr>
<tr>
<td>8743/3: Superficial spreading</td>
<td>0</td>
<td>0 (0.04-9.10)</td>
<td>0</td>
<td>0 (0.03-6.27)</td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>2</td>
<td>1.65 (0.20-5.95)</td>
<td>2</td>
<td>1.22 (0.15-4.39)</td>
</tr>
<tr>
<td>8771/3: Epithelioid</td>
<td>1</td>
<td>3.31 (0.08-18.45)</td>
<td>0</td>
<td>0 (0.02-3.55)</td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>3</td>
<td>1.12 (0.23-3.28)</td>
<td>10</td>
<td>2.61 (1.25-4.80)</td>
</tr>
<tr>
<td>Radiotherapy for uveal melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6</td>
<td>1.29 (0.48-2.82)</td>
<td>3</td>
<td>0.57 (0.12-1.67)</td>
</tr>
<tr>
<td>Site of the next malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>2</td>
<td>0.87 (0.10-3.13)</td>
<td>1</td>
<td>0.39 (0.01-2.16)</td>
</tr>
<tr>
<td>Site</td>
<td>O</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>Prostate</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0.63</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>2</td>
<td>2.24</td>
<td>1</td>
<td>0.82</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>2</td>
<td>2.10</td>
<td>2</td>
<td>1.37</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2.04</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>4</td>
<td>4.30#</td>
<td>4</td>
<td>4.03#</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2.13</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>1</td>
<td>1.87</td>
<td>1</td>
<td>1.57</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2.06</td>
</tr>
<tr>
<td>Ovary</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leukemia</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2.89</td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>1</td>
<td>2.79</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>29.48</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
Supplementary table 2. Standardized incidence Ratios for developing a second malignancy after First Primary Uveal Melanoma in patients 50-70 years old; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>133</td>
<td>1.24# (1.04-1.47)</td>
<td>113</td>
<td>1.15 (0.94-1.38)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>80</td>
<td>1.24 (0.98-1.54)</td>
<td>77</td>
<td>1.25 (0.99-1.56)</td>
</tr>
<tr>
<td>Female</td>
<td>53</td>
<td>1.25 (0.93-1.63)</td>
<td>36</td>
<td>0.97 (0.68-1.34)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>132</td>
<td>1.25# (1.05-1.48)</td>
<td>112</td>
<td>1.15 (0.95-1.39)</td>
</tr>
<tr>
<td>Black</td>
<td>1</td>
<td>1.43 (0.04-7.97)</td>
<td>1</td>
<td>2.17 (0.05-12.10)</td>
</tr>
<tr>
<td>Other races</td>
<td>0</td>
<td></td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Primary site of uveal melanoma a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>111</td>
<td>1.23# (1.01-1.48)</td>
<td>90</td>
<td>1.12 (0.90-1.37)</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>22</td>
<td>1.29 (0.81-1.96)</td>
<td>23</td>
<td>1.27 (0.81-1.91)</td>
</tr>
<tr>
<td>Histology of uveal melanoma b</td>
<td>8720/3: Malignant melanoma, NOS</td>
<td>85</td>
<td>1.22 (0.98-1.51)</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>8730/3: Amelanotic</td>
<td>2</td>
<td>2.16 (0.26-7.81)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>8743/3: Superficial spreading</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>20</td>
<td>1.59 (0.97-2.45)</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>8771/3: Epithelioid</td>
<td>3</td>
<td>0.61 (0.13-1.80)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>8772-8774/3: Spindle cell</td>
<td>23</td>
<td>1.20 (0.76-1.80)</td>
<td>28</td>
</tr>
<tr>
<td>Radiotherapy for uveal melanoma</td>
<td>Yes</td>
<td>55</td>
<td>1.15 (0.87-1.50)</td>
<td>51</td>
</tr>
<tr>
<td>Site of the next malignancy c</td>
<td>Breast</td>
<td>13</td>
<td>0.96 (0.51-1.64)</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Prostate</td>
<td>29</td>
<td>1.43 (0.76-2.86)</td>
<td>22</td>
</tr>
<tr>
<td>Site</td>
<td>Cases</td>
<td>Rate (95% CI)</td>
<td>P value</td>
<td>Significant (P &lt; 0.05)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------</td>
<td>---------------</td>
<td>---------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>15</td>
<td>0.13 (0.75-2.22)</td>
<td>0.89 (0.54-1.40)</td>
<td>0.93 (0.67-1.27)</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>11</td>
<td>0.67 (0.33-1.20)</td>
<td>1.28 (0.78-1.98)</td>
<td>1.04 (0.80-1.33)</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>5</td>
<td>0.94 (0.31-2.20)</td>
<td>4 (0.20-1.90)</td>
<td>0.89 (0.47-1.26)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>15</td>
<td>3.73 (2.08-6.14)</td>
<td>6 (0.62-3.70)</td>
<td>13 (1.03-3.29)</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>11</td>
<td>0.67 (0.33-1.20)</td>
<td>20 (0.78-1.98)</td>
<td>32 (0.76-1.57)</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>5</td>
<td>0.94 (0.31-2.20)</td>
<td>4 (0.20-1.90)</td>
<td>9 (0.35-1.44)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>15</td>
<td>3.73 (2.08-6.14)</td>
<td>6 (0.62-3.70)</td>
<td>13 (1.03-3.29)</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>2</td>
<td>0.56 (0.07-2.02)</td>
<td>3 (0.23-3.24)</td>
<td>11 (0.60-3.55)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>4</td>
<td>1.02 (0.28-2.61)</td>
<td>2 (0.07-1.94)</td>
<td>9 (0.53-2.20)</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>3</td>
<td>0.95 (0.20-2.76)</td>
<td>3 (0.25-3.48)</td>
<td>2 (0.07-7.94)</td>
</tr>
<tr>
<td>Thyroid</td>
<td>5</td>
<td>4.11 (1.33-9.59)</td>
<td>0 (0.02-4.80)</td>
<td>6 (0.67-3.99)</td>
</tr>
<tr>
<td>Ovary</td>
<td>2</td>
<td>1.29 (0.16-4.67)</td>
<td>1 (0.02-4.45)</td>
<td>2 (0.11-3.40)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2</td>
<td>0.76 (0.09-2.73)</td>
<td>3 (0.24-3.40)</td>
<td>8 (0.61-2.79)</td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>8</td>
<td>2.63 (1.14-5.18)</td>
<td>5 (0.60-4.28)</td>
<td>9 (0.87-3.60)</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>1</td>
<td>5.05 (0.13-28.16)</td>
<td>1 (0.15-33.84)</td>
<td>6 (0.87-25.89)</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
Supplementary table 3. Standardized incidence Ratios for developing a second malignancy after First Primary Uveal Melanoma in patients 70 years old or older; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>110</td>
<td>1.13 (0.93-1.37)</td>
<td>48</td>
<td>0.91 (0.67-1.21)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>65</td>
<td>1.11 (0.86-1.41)</td>
<td>29</td>
<td>0.93 (0.62-1.33)</td>
</tr>
<tr>
<td>Female</td>
<td>45</td>
<td>1.17 (0.85-1.56)</td>
<td>19</td>
<td>0.89 (0.54-1.40)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>109</td>
<td>1.14 (0.93-1.37)</td>
<td>48</td>
<td>0.92 (0.68-1.22)</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other races</td>
<td>1</td>
<td>2.85 (0.07-15.90)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Primary site of uveal melanoma a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>93</td>
<td>1.13 (0.91-1.38)</td>
<td>37</td>
<td>0.83 (0.58-1.14)</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>17</td>
<td>1.15 (0.67-1.85)</td>
<td>11</td>
<td>1.39 (0.69-2.48)</td>
</tr>
<tr>
<td>Histology of uveal melanoma b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8720/3: Malignant melanoma, NOS</td>
<td>67</td>
<td>1.05 (0.82-1.34)</td>
<td>32</td>
<td>0.97 (0.66-1.36)</td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8743/3: Superficial spreading</td>
<td>1</td>
<td>7.18 (0.18-40.01)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>20</td>
<td>1.74# (1.06-2.69)</td>
<td>3</td>
<td>0.60 (0.12-1.75)</td>
</tr>
<tr>
<td>8771/3: Epithelioid</td>
<td>3</td>
<td>0.69 (0.14-2.02)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>19</td>
<td>1.11 (0.67-1.73)</td>
<td>13</td>
<td>1.09 (0.58-1.86)</td>
</tr>
<tr>
<td>Radiotherapy for uveal melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>42</td>
<td>1.06 (0.76-1.43)</td>
<td>16</td>
<td>0.82 (0.47-1.33)</td>
</tr>
<tr>
<td>Site of the next malignancy c</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>6</td>
<td>0.64 (0.23-1.39)</td>
<td>3</td>
<td>0.61 (0.13-1.78)</td>
</tr>
<tr>
<td>Prostate</td>
<td>16</td>
<td>0.96 (0.62-1.60)</td>
<td>5</td>
<td>0.60 (0.22-1.60)</td>
</tr>
<tr>
<td>Tissue Type</td>
<td>Observed</td>
<td>95% CI Lower</td>
<td>95% CI Upper</td>
<td>95% CI Lower</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>0.66</td>
<td>(0.30-1.26)</td>
<td>0.97</td>
<td>(0.32-2.27)</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>0.66</td>
<td>(0.32-1.22)</td>
<td>1.03</td>
<td>(0.01-1.27)</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.91</td>
<td>(0.33-1.97)</td>
<td>1.16</td>
<td>(0.85-5.02)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>1.17</td>
<td>(0.33-1.22)</td>
<td>3.47</td>
<td>(0.82-2.18)</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0.55</td>
<td>(0.01-3.06)</td>
<td>1.75</td>
<td>(0.14-4.21)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0.44</td>
<td>(0.01-2.46)</td>
<td>1.75</td>
<td>(1.82-6.53)</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>0.99</td>
<td>(0.03-5.54)</td>
<td>1.52</td>
<td>(0.31-4.45)</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.99</td>
<td>(0.01-2.46)</td>
<td>4.16</td>
<td>(0.50-15.02)</td>
</tr>
<tr>
<td>Ovary</td>
<td>0.87</td>
<td>(0.01-2.46)</td>
<td>1.52</td>
<td>(0.31-4.45)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>0.94</td>
<td>(0.19-2.73)</td>
<td>3.09</td>
<td>(0.02-4.84)</td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>0.94</td>
<td>(0.19-2.73)</td>
<td>3.09</td>
<td>(0.02-4.84)</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>13.6#</td>
<td>(1.65-49.15)</td>
<td>25.0</td>
<td>(2.0-126.7)</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
### Supplementary table 4. Standardized incidence Ratios for developing a second malignancy after First Primary Uveal Melanoma in white patients; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>256</td>
<td>180</td>
<td>283</td>
<td>719</td>
</tr>
<tr>
<td></td>
<td>1.21#</td>
<td>1.10</td>
<td>1.02</td>
<td>1.10#</td>
</tr>
<tr>
<td></td>
<td>(0.95-1.28)</td>
<td>(0.90-1.14)</td>
<td>(1.02-1.18)</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>152</td>
<td>115</td>
<td>166</td>
<td>433</td>
</tr>
<tr>
<td></td>
<td>1.20#</td>
<td>1.16</td>
<td>0.98</td>
<td>1.09</td>
</tr>
<tr>
<td></td>
<td>(1.01-1.40)</td>
<td>(0.96-1.39)</td>
<td>(0.83-1.14)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>104</td>
<td>65</td>
<td>117</td>
<td>286</td>
</tr>
<tr>
<td></td>
<td>1.22</td>
<td>1.02</td>
<td>1.08</td>
<td>1.11</td>
</tr>
<tr>
<td></td>
<td>(1.00-1.48)</td>
<td>(0.79-1.30)</td>
<td>(0.90-1.30)</td>
<td></td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50 years</td>
<td>15</td>
<td>20</td>
<td>68</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>1.41</td>
<td>1.46</td>
<td>0.98</td>
<td>1.10</td>
</tr>
<tr>
<td></td>
<td>(0.79-2.33)</td>
<td>(0.89-2.26)</td>
<td>(0.90-1.33)</td>
<td></td>
</tr>
<tr>
<td>50-69 years</td>
<td>132</td>
<td>112</td>
<td>179</td>
<td>423</td>
</tr>
<tr>
<td></td>
<td>1.25#</td>
<td>1.15</td>
<td>1.02</td>
<td>1.12#</td>
</tr>
<tr>
<td></td>
<td>(1.05-1.48)</td>
<td>(0.95-1.39)</td>
<td>(0.87-1.18)</td>
<td></td>
</tr>
<tr>
<td>70 years or more</td>
<td>109</td>
<td>48</td>
<td>36</td>
<td>193</td>
</tr>
<tr>
<td></td>
<td>1.14</td>
<td>0.92</td>
<td>1.11</td>
<td>1.07</td>
</tr>
<tr>
<td></td>
<td>(0.93-1.37)</td>
<td>(0.79-1.30)</td>
<td>(0.90-1.30)</td>
<td></td>
</tr>
<tr>
<td><strong>Primary site of uveal melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>215</td>
<td>139</td>
<td>216</td>
<td>570</td>
</tr>
<tr>
<td></td>
<td>1.20#</td>
<td>1.03</td>
<td>1.01</td>
<td>1.08</td>
</tr>
<tr>
<td></td>
<td>(1.05-1.38)</td>
<td>(0.87-1.22)</td>
<td>(0.88-1.16)</td>
<td></td>
</tr>
<tr>
<td>Ciliary body</td>
<td>41</td>
<td>41</td>
<td>67</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>1.22</td>
<td>1.43#</td>
<td>1.04</td>
<td>1.18</td>
</tr>
<tr>
<td></td>
<td>(0.88-1.66)</td>
<td>(1.03-1.95)</td>
<td>(0.80-1.32)</td>
<td></td>
</tr>
<tr>
<td><strong>Histology of uveal melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8720/3: Malignant melanoma, NOS</td>
<td>160</td>
<td>110</td>
<td>174</td>
<td>444</td>
</tr>
<tr>
<td></td>
<td>1.16</td>
<td>1.09</td>
<td>1.10</td>
<td>1.12#</td>
</tr>
<tr>
<td></td>
<td>(0.99-1.36)</td>
<td>(0.90-1.32)</td>
<td>(0.94-1.27)</td>
<td></td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>1.54</td>
<td>1.79</td>
<td>1.44</td>
<td>1.58</td>
</tr>
<tr>
<td></td>
<td>(0.19-5.58)</td>
<td>(0.22-6.47)</td>
<td>(0.17-5.19)</td>
<td></td>
</tr>
<tr>
<td>8743/3: Superficial spreading</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>7.18</td>
<td>0.72</td>
<td>0.78</td>
<td>1.93</td>
</tr>
<tr>
<td></td>
<td>(0.18-40.01)</td>
<td>(0.38-1.22)</td>
<td>(0.88-1.66)</td>
<td></td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>42</td>
<td>13</td>
<td>41</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>1.68#</td>
<td>0.72</td>
<td>1.23</td>
<td>1.25#</td>
</tr>
<tr>
<td></td>
<td>(1.21-2.27)</td>
<td>(0.38-1.22)</td>
<td>(0.88-1.66)</td>
<td></td>
</tr>
<tr>
<td>8771/3: Epithelioid</td>
<td>6</td>
<td>4</td>
<td>7</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>0.64</td>
<td>0.69</td>
<td>0.78</td>
<td>0.70</td>
</tr>
<tr>
<td></td>
<td>(0.24-1.40)</td>
<td>(0.19-1.76)</td>
<td>(0.31-1.60)</td>
<td></td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>45</td>
<td>51</td>
<td>59</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>1.17</td>
<td>1.38#</td>
<td>0.78</td>
<td>1.03</td>
</tr>
<tr>
<td></td>
<td>(0.85-1.56)</td>
<td>(1.02-1.81)</td>
<td>(0.60-1.01)</td>
<td></td>
</tr>
<tr>
<td><strong>Radiotherapy for uveal melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>102</td>
<td>69</td>
<td>69</td>
<td>240</td>
</tr>
<tr>
<td></td>
<td>1.13</td>
<td>1.10</td>
<td>1.04</td>
<td>1.09</td>
</tr>
<tr>
<td></td>
<td>(0.92-1.37)</td>
<td>(0.86-1.40)</td>
<td>(0.81-1.31)</td>
<td></td>
</tr>
<tr>
<td><strong>Site of the next malignancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>20</td>
<td>17</td>
<td>29</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>0.81</td>
<td>0.93</td>
<td>0.98</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>(0.49-1.24)</td>
<td>(0.54-1.48)</td>
<td>(0.66-1.41)</td>
<td></td>
</tr>
<tr>
<td>Site</td>
<td>Cases</td>
<td>Observed</td>
<td>95% CI</td>
<td>Expected</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------</td>
<td>----------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td>Prostate</td>
<td>45</td>
<td>1.21</td>
<td>(0.89-1.62)</td>
<td>28</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>26</td>
<td>1.03</td>
<td>(0.67-1.51)</td>
<td>15</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>23</td>
<td>0.72</td>
<td>(0.46-1.08)</td>
<td>30</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>11</td>
<td>0.91</td>
<td>(0.45-1.62)</td>
<td>11</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>30</td>
<td>3.79#</td>
<td>(2.56-5.42)</td>
<td>12</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>3</td>
<td>0.53</td>
<td>(0.11-1.55)</td>
<td>6</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>12</td>
<td>1.44</td>
<td>(0.74-2.51)</td>
<td>4</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>6</td>
<td>1.10</td>
<td>(0.40-2.40)</td>
<td>4</td>
</tr>
<tr>
<td>Thyroid</td>
<td>7</td>
<td>3.24#</td>
<td>(1.30-6.67)</td>
<td>1</td>
</tr>
<tr>
<td>Ovary</td>
<td>3</td>
<td>1.04</td>
<td>(0.21-3.04)</td>
<td>1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>5</td>
<td>0.82</td>
<td>(0.27-1.92)</td>
<td>7</td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>14</td>
<td>2.48#</td>
<td>(1.36-4.17)</td>
<td>5</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>3</td>
<td>8.08#</td>
<td>(1.67-23.61)</td>
<td>2</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
**Supplementary Table 5.** Standardized incidence ratios for developing a primary uveal melanoma following another primary malignancy in patients **younger than 50 years** at diagnosis of first cancer; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>7</td>
<td>0.80 (0.32-1.65)</td>
<td>18</td>
<td>1.78# (1.06-2.82)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2</td>
<td>0.57 (0.07-2.05)</td>
<td>5</td>
<td>1.25 (0.41-2.91)</td>
</tr>
<tr>
<td>Female</td>
<td>5</td>
<td>0.96 (0.31-2.23)</td>
<td>13</td>
<td>2.14# (1.14-3.65)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>7</td>
<td>0.83 (0.33-1.70)</td>
<td>18</td>
<td>1.83# (1.09-2.90)</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other races</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Primary site of uveal melanoma</strong> a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>5</td>
<td>1.43 (0.17-5.16)</td>
<td>2</td>
<td>1.44 (0.17-5.19)</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>2</td>
<td>1.61 (0.80-2.88)</td>
<td>11</td>
<td>1.61 (0.80-2.88)</td>
</tr>
<tr>
<td><strong>Histology of uveal melanoma</strong> b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8720/3: Malignant, NOS</td>
<td>5</td>
<td>1.25 (0.26-3.65)</td>
<td>7</td>
<td>2.46 (0.99-5.07)</td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>8771/3: Epithelioid cell</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>2</td>
<td>1.10 (0.13-3.99)</td>
<td>5</td>
<td>2.84 (0.92-6.62)</td>
</tr>
<tr>
<td><strong>Site of the first malignancy</strong> c</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>3</td>
<td>1.25 (0.26-3.65)</td>
<td>7</td>
<td>2.46 (0.99-5.07)</td>
</tr>
<tr>
<td>Prostate</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>1</td>
<td>4.29 (0.11-23.91)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>3</td>
<td>3.03 (0.63-8.86)</td>
<td>3</td>
<td>2.41 (0.50-7.03)</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Ovary</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Obs.</td>
<td>#</td>
<td>a</td>
<td>b</td>
</tr>
<tr>
<td>----------------------</td>
<td>------</td>
<td>---</td>
<td>-----</td>
<td>---</td>
</tr>
<tr>
<td>Leukemia</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>5.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and renal</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>3.46</td>
</tr>
<tr>
<td>pelvis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Radiotherapy for the first malignancy**

<table>
<thead>
<tr>
<th></th>
<th>Obs.</th>
<th>#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>1</td>
<td>0.36</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
### Supplementary Table 6. Standardized incidence ratios for developing a primary uveal melanoma following another primary malignancy in patients between 50-70 years at diagnosis of first cancer; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SIR (95% CI)</td>
<td>SIR (95% CI)</td>
<td>SIR (95% CI)</td>
<td>SIR (95% CI)</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>79</td>
<td>1.01 (0.80-1.26)</td>
<td>74</td>
<td>1.15 (0.91-1.45)</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>47</td>
<td>1.01 (0.74-1.35)</td>
<td>42</td>
<td>1.11 (0.80-1.51)</td>
<td>43</td>
</tr>
<tr>
<td>Female</td>
<td>32</td>
<td>1.01 (0.69-1.43)</td>
<td>32</td>
<td>1.21 (0.83-1.71)</td>
<td>46</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>77</td>
<td>1.01 (0.79-1.25)</td>
<td>72</td>
<td>1.14 (0.89-1.44)</td>
<td>87</td>
</tr>
<tr>
<td>Black</td>
<td>1</td>
<td>2.26 (0.06-12.59)</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Other races</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>9.30# (1.13-33.61)</td>
<td>1</td>
</tr>
<tr>
<td>Primary site of uveal melanoma *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>65</td>
<td>0.97 (0.75-1.23)</td>
<td>62</td>
<td>1.11 (0.85-1.42)</td>
<td>73</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>14</td>
<td>1.31 (0.71-1.99)</td>
<td>12</td>
<td>1.45 (0.75-2.52)</td>
<td>16</td>
</tr>
<tr>
<td>Histology of uveal melanoma a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8720/3: Malignant, NOS</td>
<td>56</td>
<td>1.07 (0.81-1.39)</td>
<td>62</td>
<td>1.41# (1.08-1.81)</td>
<td>62</td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>12</td>
<td>1.32 (0.68-2.30)</td>
<td>5</td>
<td>0.67 (0.22-1.57)</td>
<td>11</td>
</tr>
<tr>
<td>8771/3: Epithelioid cell</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0.64 (0.08-2.32)</td>
<td>2</td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>11</td>
<td>0.91 (0.45-1.63)</td>
<td>5</td>
<td>0.55 (0.18-1.29)</td>
<td>11</td>
</tr>
<tr>
<td>Site of the first malignancy *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>11</td>
<td>0.82 (0.41-1.46)</td>
<td>12</td>
<td>0.99 (0.51-1.73)</td>
<td>23</td>
</tr>
<tr>
<td>Prostate</td>
<td>23</td>
<td>1.10 (0.69-1.64)</td>
<td>22</td>
<td>1.17 (0.74-1.78)</td>
<td>15</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>8</td>
<td>0.96 (0.41-1.89)</td>
<td>11</td>
<td>1.59 (0.80-2.85)</td>
<td>14</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>2</td>
<td>0.23 (0.01-1.28)</td>
<td>3</td>
<td>1.37 (0.28-4.01)</td>
<td>3</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>4</td>
<td>0.88 (0.24-2.26)</td>
<td>2</td>
<td>0.49 (0.06-1.78)</td>
<td>7</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>6</td>
<td>1.63 (0.60-3.54)</td>
<td>5</td>
<td>1.55 (0.50-3.61)</td>
<td>11</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>4</td>
<td>1.02 (0.28-2.61)</td>
<td>2</td>
<td>0.54 (0.07-1.97)</td>
<td>5</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>2</td>
<td>0.68 (0.08-2.44)</td>
<td>1</td>
<td>0.45 (0.01-2.48)</td>
<td>2</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>4</td>
<td>1.69 (0.46-4.33)</td>
<td>3</td>
<td>1.72 (0.36-5.03)</td>
<td>1</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
<table>
<thead>
<tr>
<th>Site</th>
<th>Obs.</th>
<th>NPV</th>
<th>TPV</th>
<th>FDR</th>
<th>importance</th>
<th>Ratio</th>
<th>95% CI</th>
<th>Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid</td>
<td>5</td>
<td>4.06</td>
<td>4.97</td>
<td>0</td>
<td>3.93</td>
<td>3.93</td>
<td>(1.32-9.47)</td>
<td>4</td>
<td>(1.07-10.06)</td>
</tr>
<tr>
<td>Ovary</td>
<td>3</td>
<td>3.03</td>
<td>3.36</td>
<td>0</td>
<td>1.61</td>
<td>1.61</td>
<td>(0.04-8.96)</td>
<td>2</td>
<td>(0.23-6.78)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2</td>
<td>1.18</td>
<td>1.58</td>
<td>0</td>
<td>2.49</td>
<td>2.49</td>
<td>(0.51-7.28)</td>
<td>0</td>
<td>(0.01-8.96)</td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>3</td>
<td>1.39</td>
<td>1.77</td>
<td>0</td>
<td>0.60</td>
<td>0.60</td>
<td>(0.02-3.37)</td>
<td>1</td>
<td>(0.01-2.77)</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>19.43</td>
<td>19.43</td>
<td>(0.49-108.25)</td>
<td>1</td>
<td>(0.19-40.76)</td>
</tr>
<tr>
<td>Radiotherapy for the first malignancy</td>
<td>24</td>
<td>1.03</td>
<td>1.54</td>
<td>0.88</td>
<td>1.30</td>
<td>1.30</td>
<td>(0.50-1.43)</td>
<td>28</td>
<td>(0.86-1.88)</td>
</tr>
<tr>
<td>Yes</td>
<td>16</td>
<td>0.88</td>
<td>1.43</td>
<td>0.50</td>
<td>1.08</td>
<td>1.08</td>
<td>(0.86-1.37)</td>
<td>68</td>
<td>(0.86-1.88)</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
**Supplementary Table 7.** Standardized incidence ratios for developing a primary uveal melanoma following another primary malignancy in patients **70 years or more** at diagnosis of first cancer; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
<td>Obs.</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>80</td>
<td>1.18 (0.94-1.47)</td>
<td>40</td>
<td>1.13 (0.81-1.54)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>47</td>
<td>1.10 (0.81-1.47)</td>
<td>30</td>
<td>1.35 (0.91-1.93)</td>
</tr>
<tr>
<td>Female</td>
<td>33</td>
<td>1.33 (0.91-1.86)</td>
<td>10</td>
<td>0.75 (0.36-1.39)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>80</td>
<td>1.20 (0.95-1.50)</td>
<td>40</td>
<td>1.14 (0.82-1.56)</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other races</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Primary site of uveal melanoma *</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>67</td>
<td>1.17 (0.91-1.49)</td>
<td>33</td>
<td>1.09 (0.75-1.53)</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>13</td>
<td>1.24 (0.66-2.12)</td>
<td>7</td>
<td>1.39 (0.56-2.86)</td>
</tr>
<tr>
<td>Histology of uveal melanoma #</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8720/3: Malignant, NOS</td>
<td>49</td>
<td>1.10 (0.81-1.45)</td>
<td>25</td>
<td>1.03 (0.67-1.52)</td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>1</td>
<td>3.24 (0.08-18.03)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>10</td>
<td>1.05 (0.51-1.94)</td>
<td>8</td>
<td>1.64 (0.71-3.22)</td>
</tr>
<tr>
<td>8771/3: Epithelioid cell</td>
<td>6</td>
<td>1.82 (0.67-3.95)</td>
<td>3</td>
<td>1.82 (0.37-5.31)</td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>14</td>
<td>1.45 (0.79-2.43)</td>
<td>4</td>
<td>0.89 (0.24-2.28)</td>
</tr>
<tr>
<td>Site of the first malignancy ^</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>18</td>
<td>1.88# (1.12-2.98)</td>
<td>5</td>
<td>0.88 (0.29-2.05)</td>
</tr>
<tr>
<td>Prostate</td>
<td>26</td>
<td>1.21 (0.79-1.77)</td>
<td>23</td>
<td>1.78# (1.13-2.67)</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>10</td>
<td>1.03 (0.49-1.89)</td>
<td>3</td>
<td>0.59 (0.12-1.72)</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>3</td>
<td>0.82 (0.17-2.40)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>8</td>
<td>1.50 (0.65-2.95)</td>
<td>3</td>
<td>1.11 (0.23-3.23)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>2</td>
<td>0.85 (0.10-3.06)</td>
<td>2</td>
<td>1.64 (0.20-5.92)</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>4</td>
<td>2.06 (0.56-5.27)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>3</td>
<td>1.19 (0.25-3.49)</td>
<td>1</td>
<td>0.89 (0.02-4.97)</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>1</td>
<td>0.75 (0.02-4.17)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ovary</td>
<td>2</td>
<td>3.73</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3.06 (0.37-11.04)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1.43 (0.04-7.98)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>1</td>
<td>22.26 (0.56-124)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Radiotherapy for the first malignancy</td>
<td>19</td>
<td>1.06 (0.64-1.65)</td>
<td>12</td>
<td>1.18 (0.61-2.05)</td>
<td>7</td>
<td>1.43 (0.57-2.94)</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode
**Supplementary Table 8.** Standardized incidence ratios for developing a primary uveal melanoma following another primary malignancy in white patients; SIR (95% confidence intervals)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>&lt; 5 years</th>
<th>S-5 years</th>
<th>&gt; 10 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>164</td>
<td>130</td>
<td>141</td>
<td>435</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>95</td>
<td>77</td>
<td>69</td>
<td>241</td>
</tr>
<tr>
<td>Female</td>
<td>69</td>
<td>53</td>
<td>72</td>
<td>194</td>
</tr>
<tr>
<td><strong>Age at diagnosis at the first malignancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50 years</td>
<td>7</td>
<td>18</td>
<td>40</td>
<td>65</td>
</tr>
<tr>
<td>50-70 years</td>
<td>77</td>
<td>72</td>
<td>87</td>
<td>236</td>
</tr>
<tr>
<td>&gt;70 years</td>
<td>80</td>
<td>40</td>
<td>14</td>
<td>134</td>
</tr>
<tr>
<td><strong>Primary site of uveal melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>29</td>
<td>20</td>
<td>26</td>
<td>75</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>135</td>
<td>110</td>
<td>115</td>
<td>360</td>
</tr>
<tr>
<td><strong>Site of the first malignancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>32</td>
<td>23</td>
<td>39</td>
<td>94</td>
</tr>
<tr>
<td>Prostate</td>
<td>49</td>
<td>45</td>
<td>116</td>
<td>1.16</td>
</tr>
<tr>
<td>Colon and rectum</td>
<td>18</td>
<td>15</td>
<td>21</td>
<td>54</td>
</tr>
<tr>
<td>Lung and bronchus</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>12</td>
<td>6</td>
<td>9</td>
<td>27</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>11</td>
<td>10</td>
<td>17</td>
<td>38</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>8</td>
<td>2</td>
<td>6</td>
<td>16</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>Oral cavity and pharynx</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>Thyroid</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td><strong>Amelanotic</strong></td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td><strong>Epithelioid</strong></td>
<td>22</td>
<td>13</td>
<td>19</td>
<td>54</td>
</tr>
<tr>
<td><strong>Mixed</strong></td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td><strong>Spindle cell</strong></td>
<td>27</td>
<td>14</td>
<td>15</td>
<td>56</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Obs.</th>
<th>SMR (95% CI)</th>
<th>OR (95% CI)</th>
<th>95% CI</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovary</td>
<td>5</td>
<td>2.96</td>
<td>1.01</td>
<td>1.47</td>
<td>1.91</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2</td>
<td>0.58</td>
<td>6.29#</td>
<td>0.51</td>
<td>1.20</td>
</tr>
<tr>
<td>Kidney and renal pelvis</td>
<td>2</td>
<td>0.52</td>
<td>6.29#</td>
<td>0.33</td>
<td>0.63</td>
</tr>
<tr>
<td>Eye and orbit</td>
<td>1</td>
<td>10.15</td>
<td>9.81</td>
<td>2.50</td>
<td>7.50</td>
</tr>
</tbody>
</table>

**Radiotherapy for the first malignancy**

<table>
<thead>
<tr>
<th>Yes</th>
<th>43</th>
<th>0.99 (0.72-1.34)</th>
<th>1.03 (0.71-1.46)</th>
<th>1.30 (0.95-1.73)</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>1.03 (0.71-1.46)</td>
<td>1.30 (0.95-1.73)</td>
<td>1.10 (0.91-1.32)</td>
<td>7.50 (0.91-27.10)</td>
</tr>
</tbody>
</table>

Acronyms: Obs., Observed; #, significant with P value less than .05; a, using primary site variable, b, using ICD-O-3 histology recode; c, using ICD-O-3 site recode.
**Supplementary Table 9.** Standardized incidence Ratios for developing a second malignancy after First Primary Uveal Melanoma according to latency; SIR (95% confidence intervals) (A complimentary to Table 4)

<table>
<thead>
<tr>
<th>Histology of uveal melanoma*</th>
<th>8720/3: Malignant melanoma, NOS</th>
<th>8730/3: Amelanotic</th>
<th>8743/3: Superficial spreading</th>
<th>8770/3: Mixed epithelioid and spindle cell</th>
<th>8771/3: Epithelioid</th>
<th>8772-8774/3: Spindle cell</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>161</td>
<td>2</td>
<td>1</td>
<td>42</td>
<td>7</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>1.15 (0.98-1.34)</td>
<td>1.45 (0.18-5.25)</td>
<td>7.18 (0.18-40.01)</td>
<td>1.66# (1.20-2.24)</td>
<td>0.74 (0.295-1.51)</td>
<td>1.15 (0.84-1.54)</td>
</tr>
<tr>
<td></td>
<td>1.09 (0.89-1.31)</td>
<td>1.73 (0.21-6.26)</td>
<td>0</td>
<td>0.71 (0.38-1.21)</td>
<td>0.68 (0.184-1.733)</td>
<td>1.36# (1.01-1.79)</td>
</tr>
<tr>
<td></td>
<td>1.09 (0.93-1.26)</td>
<td>1.42 (0.17-5.13)</td>
<td>0</td>
<td>1.25 (0.90-1.69)</td>
<td>0.78 (0.31-1.60)</td>
<td>0.78 (0.59-1.00)</td>
</tr>
<tr>
<td></td>
<td>449</td>
<td>6</td>
<td>1</td>
<td>97</td>
<td>18</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>1.11# (1.01-1.22)</td>
<td>1.52 (0.56-3.32)</td>
<td>1.93 (0.05-10.77)</td>
<td>1.26# (1.02-1.53)</td>
<td>0.74 (0.44-1.16)</td>
<td>1.02 (0.86-1.19)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Radiotherapy for uveal melanoma</th>
<th>8770/3: Mixed epithelioid and spindle cell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>1.12 (0.91-1.36)</td>
</tr>
</tbody>
</table>

**Acronyms:** a, using ICD-O-3 histology recode
**Supplementary Table 10.** Standardized incidence ratios for developing a primary uveal melanoma following another primary malignancy according to the latency; SIR (95% confidence intervals). (A complimentary to Table 5)

<table>
<thead>
<tr>
<th>Histology of uveal melanoma*</th>
<th>N</th>
<th>SIR</th>
<th>95% CI</th>
<th>N</th>
<th>SIR</th>
<th>95% CI</th>
<th>N</th>
<th>SIR</th>
<th>95% CI</th>
<th>N</th>
<th>SIR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>8720/3: Malignant, NOS</td>
<td>110</td>
<td>1.07</td>
<td>(0.88-1.29)</td>
<td>98</td>
<td>1.31#</td>
<td>(1.06-1.59)</td>
<td>103</td>
<td>1.00</td>
<td>(0.82-1.21)</td>
<td>311</td>
<td>1.11</td>
<td>(0.99-1.24)</td>
</tr>
<tr>
<td>8730/3: Amelanotic</td>
<td>1</td>
<td>0.92</td>
<td>(0.02-5.13)</td>
<td>0</td>
<td>0</td>
<td></td>
<td>4</td>
<td>4.22#</td>
<td>(1.15-10.81)</td>
<td>5</td>
<td>1.81</td>
<td>(0.59-4.22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8770/3: Mixed epithelioid and spindle cell</td>
<td>22</td>
<td>1.13</td>
<td>(0.71-1.70)</td>
<td>14</td>
<td>1.04</td>
<td>(0.57-1.75)</td>
<td>19</td>
<td>1.19</td>
<td>(0.72-1.86)</td>
<td>55</td>
<td>1.12</td>
<td>(0.85-1.46)</td>
</tr>
<tr>
<td>8771/3: Epithelioid cell</td>
<td>6</td>
<td>0.82</td>
<td>(0.30-1.78)</td>
<td>6</td>
<td>1.19</td>
<td>(0.44-2.59)</td>
<td>2</td>
<td>0.32</td>
<td>(0.04-1.15)</td>
<td>14</td>
<td>0.75</td>
<td>(0.41-1.26)</td>
</tr>
<tr>
<td>8772-8774/3: Spindle cell</td>
<td>27</td>
<td>1.15</td>
<td>(0.76-1.67)</td>
<td>14</td>
<td>0.92</td>
<td>(0.50-1.54)</td>
<td>15</td>
<td>0.84</td>
<td>(0.47-1.38)</td>
<td>56</td>
<td>0.99</td>
<td>(0.75-1.28)</td>
</tr>
</tbody>
</table>

Acronyms: a, using ICD-O-3 histology recode